Benefits
Joint comfort: not supported by the study cited here
No joint or osteoarthritis study is cited on this page. Theracurmin has been tested in knee osteoarthritis in the wider published literature, but that research is not referenced here, so nothing on this page supports a joint claim. Osteoarthritis is a medical condition, and a supplement is not a treatment for it.
Exercise recovery: not measured in the cited study
The single trial cited on this page did not look at exercise, muscle damage or recovery. It was a 12-week study of cold symptoms and immune measures in healthy adults, so there is no evidence here for a training or recovery benefit.
Blood vessel function: not measured in the cited study
No blood vessel or circulation outcome was measured in the one study cited on this page, and no such study is referenced here. Nothing on this page supports a heart or blood vessel claim.
Cognitive function in older adults
The only study cited on this page measured cold symptoms and immune markers, not memory or attention. Theracurmin has been studied for cognition elsewhere in the published literature, but that work is not cited here, so this page cannot claim a brain benefit. Talk of anti-amyloid effects comes from Alzheimer's disease research and is not something a supplement can be presented as doing.
Better absorption than plain curcumin (manufacturer figure)
The colloidal nanoparticle form is designed to get more curcumin into the blood than plain curcumin powder, which is why the doses are small. The absorption figures come from the manufacturer and are not from any study cited on this page. Better absorption is a property of the ingredient, not a health benefit in itself.
Immune and inflammatory measures: studied, but results not detailed
The one trial cited here did measure immune and inflammatory function alongside cold symptoms, in healthy Japanese adults taking 150 mg a day for 12 weeks. The published summary reports only the cold symptom result in detail, so the inflammatory findings should not be overstated. No specific drop in CRP or IL-6 is documented by the reference on this page.
Liver: no liver study is cited here
No liver measurement of any kind appears in the study cited on this page. Fatty liver disease is a medical condition diagnosed and managed by a doctor, and nothing referenced here shows that this supplement changes liver enzymes or liver fat.
Mechanism of action
Colloidal nanoparticle dispersion (how the form differs)
Curcumin (diferuloylmethane) is dispersed with colloidal nanoparticles via Theravalues' proprietary manufacturing process. The maker says the nanoparticle form helps curcumin cross the gut lining, which plain crystalline curcumin does poorly because it barely dissolves in water. It is a different approach from other enhanced-absorption curcumin forms such as Meriva, Longvida, BCM-95 and CurQfen. None of these absorption comparisons come from a study cited on this page.
Increased intestinal endothelium penetrability
Nanoparticle dispersion is intended to help curcumin pass through the gut wall, which plain crystalline curcumin struggles to do because it hardly dissolves in water. This is the manufacturer's explanation for the higher blood levels; no absorption study is cited on this page.
NF-κB anti-inflammatory pathway suppression
Curcumin's core anti-inflammatory mechanism via NF-κB pathway suppression. This pathway work comes from laboratory research on curcumin in general, not from any human study of this branded product cited on this page.
Getting into the brain (proposed, not shown here)
It is proposed that the better absorbed form reaches the brain more easily than plain curcumin. This is a theory, not something measured in the study cited on this page, and no brain or memory outcome is documented here.
Amyloid and tau (dementia research, not cited here)
Brain scan findings on amyloid and tau come from Alzheimer's disease research that is not cited anywhere on this page. Amyloid and tau are markers studied in dementia research, and nothing referenced here shows that this supplement changes them or affects any disease process.
Antioxidant via direct ROS scavenging and Nrf2 activation
Curcumin can neutralize reactive oxygen species and switch on the Nrf2 antioxidant pathway in laboratory studies. Whether this happens in people at the doses used is not shown by any study cited on this page.
Clinical trials
The single study cited on this page: cold symptoms and immune measures in healthy Japanese adults.
Clinical population described in trial publication.
Kuwabara Y and colleagues, Journal of Dietary Supplements 2024 (PMID 36927282). Randomized, double-blind, placebo-controlled trial in healthy Japanese adults; 94 people completed it (30 on placebo, 32 on Theracurmin Super TS-P1, 33 on Theracurmin CR-033P) taking 150 mg a day for 12 weeks. Both curcumin groups had significantly fewer total days with cold symptoms than placebo. Immune and inflammatory function was also measured, but the published summary details only the cold symptom result, so those findings should not be overstated. No memory, joint or liver outcome was measured in this study.
Theravalues 6-month MCI/AD stabilization trial (n=93).
Clinical population described in trial publication.
This is a manufacturer-reported study with no publication, no reference and no PMID on this page, so its results cannot be checked. It was run in people already diagnosed with mild cognitive impairment or Alzheimer's disease, which is a medical setting and says nothing about what a supplement does for a healthy person. Treat it as a company claim, not as evidence.
UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day.
Clinical population described in trial publication.
A university-sponsored 12-month study of Theracurmin Super at 75 mg a day is listed as planned and not yet recruiting. No participants have been enrolled, so no data and no results exist. It is not evidence of anything.